H1 Presentation and Q&A

Erstatter tidligere spørgsmål som bedes slettet grundet at det ikke giver mening (sorry:-))!
Da for eksempel NOVO er meget fokuseret på nyrer, burde SuPAR så ikke være noget der mere eller mindre burde være et must test i deres forskning og studier, idet SuPAR har stor forbindelse til netop nyrerne, herunder måske endda kausal?

Da eksempelvis NOVO er meget fokuseret på nyrer, burde SuPAR så ikke være noget der minder om et must i deres forskning og studier idet SuPAR har stor forbindelse til netop nyrerne, herunder måske endda kausal?

Recurring customers were essentially flat despite the revenue surge, and North America effectively one partner drove the majority of H1 revenue. How concentrated is the business today, and does the new model broaden the recurring base or does near-term growth deepen reliance on a small number of large orders?

You're pivoting to a partnership-led, business-development model at the same moment your VP Sales & Marketing departs (end of September) and a newly hired VP of BD is still ramping. How many partnership discussions are genuinely in the pipeline, and when do you expect the first new agreement beyond suPARbio to sign and contribute revenue?

You ended the period with ~DKK 17.6m in cash and say you expect the FDA to request additional data, which you describe as a significant commitment for the year ahead. Roughly what does that data package cost?

The 173% revenue jump was driven by suPARbio taking delivery of its minimum binding order, which now sits as stock at the partner rather than end-user testing. What visibility do you have on when that inventory converts into actual testing and reorders — and should we expect a softer H2 top line before pull-through begins?